Ovid Therapeutics Shares Rise on Clinical Advances and Strategic Capital Injection

Ovid Therapeutics shares are trading higher after the company reported significant clinical pipeline advancements and solidified its financial position through the sale of ganaxolone royalty rights for $7 million.